Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD LGP
- Development stage
- Unknown
- Lead developer
- Little Green Pharma
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
CBD LGP refers to cannabidiol (CBD) products manufactured by Little Green Pharma, an Australian company specializing in medical cannabis. These products are formulated as oral or inhaled medications and are available in various ratios of CBD and THC, with "CBD LGP" typically denoting a CBD-dominant formulation. Cannabidiol is a non-intoxicating phytocannabinoid derived from Cannabis sativa that acts primarily through modulation of the endocannabinoid system. It has demonstrated anticonvulsant properties and is approved for certain seizure disorders; it also shows potential for treating anxiety, stress, insomnia, chronic pain (especially neuropathic or nociplastic pain), and other neurological conditions. The mechanism involves inhibition of voltage-dependent sodium channels and modulation of cannabinoid receptors (CB1/CB2), among others[5][8][9]. All Little Green Pharma products comply with strict Australian quality standards and are supplied under the Special Access Scheme[1][2].
- Brand names
- CBD LGP
- Other names
- CBD LGPLittle Green Pharma CBDLGP CBD
02
Targets
CNR1 (Cannabinoid receptor 1)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on CBD LGP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBD LGP.